Zepbound Side Effects: Full Breakdown by Frequency

Zepbound is the obesity and sleep-apnea brand of tirzepatide, a once-weekly injection that produces some of the largest weight loss of any approved drug. It also has a real and well-documented side-effect profile, and most of it is gastrointestinal. This guide breaks down every common Zepbound side effect by how often it actually happens — using the incidence numbers straight from the FDA prescribing information — and then walks through the more serious warnings honestly, so you know what is common and mild, what is rare and serious, and where the line sits.

The numbers below come from the Zepbound label's pooled obesity trials, where side effects were recorded across the 5 mg, 10 mg, and 15 mg maintenance doses against placebo¹. That placebo comparison matters: some symptoms (like fatigue or abdominal pain) happen to people on placebo too, so the honest measure of a drug effect is how far above the placebo rate it sits.

The big picture: Zepbound side effects are GI-dominant

If you remember one thing, make it this — the overwhelming majority of Zepbound side effects are gastrointestinal, they are dose-dependent, and they cluster during the weeks when the dose is being increased rather than at a stable maintenance dose. A systematic review across the tirzepatide trial program found GI events were generally mild to moderate, scaled with the dose, were most frequent during escalation, and were the leading reason people stopped treatment⁷. An updated meta-analysis that folded in SURMOUNT-2 reached the same conclusion: strong, dose-dependent weight loss paired with a measurable rise in GI events versus placebo⁸.

That framing is the honest one. These effects are genuinely common — most people feel some nausea at some point — but for the large majority they are manageable and ease as the body adapts. They are a tradeoff, not an emergency.

Side effects ranked by frequency (FDA label)

Here is the breakdown of adverse reactions reported in at least 5% of Zepbound users in the pooled obesity trials, ordered from most to least common. Placebo rates are shown for context, and the range spans the 5 mg to 15 mg doses¹.

Nausea — the most common. Reported by roughly 25% to 29% of people across doses, versus about 8% on placebo¹. It is usually worst in the days after a dose increase and tends to settle once you hold at a stable dose.

Diarrhea — about 19% to 23%, versus roughly 8% on placebo¹. Like nausea, it is dose-related and most common during titration.

Constipation — about 11% to 17%, versus about 5% on placebo¹. Notably, this one is more common at the lower doses in the label table — slowed gastric emptying cuts both ways. Because it stems from ongoing slowed motility rather than an acute reaction, it can persist and often needs active management; we cover why it happens and what relieves it in tirzepatide constipation: why it happens and how to get relief.

Vomiting — about 8% to 13%, versus 2% on placebo, and it climbs with the dose¹.

Abdominal pain — about 9% to 10%, versus 5% on placebo¹. Mild abdominal discomfort is common; severe, persistent, or radiating pain is not, and is a reason to call a clinician (see the pancreatitis section below).

Dyspepsia (indigestion) — about 9% to 10%, versus 4% on placebo¹.

Injection-site reactions — about 6% to 8%, versus 2% on placebo¹. Usually minor redness or irritation where the dose was given.

Fatigue — about 5% to 7%, versus 3% on placebo¹. The above-placebo signal is real but modest, and for most people it is secondary to eating less, dehydration, and rapid weight loss rather than a direct drug effect — see does tirzepatide make you tired?.

Hypersensitivity reactions — about 5%, versus 3% on placebo¹. This category covers mostly mild reactions; true anaphylaxis is a separate, rare, serious event covered below.

Eructation (burping) — about 4% to 5%, versus 1% on placebo¹. The rotten-egg, sulfur-smelling version of this is a common patient complaint without its own trial frequency — we cover the likely mechanism and fixes in tirzepatide sulfur burps.

Hair loss — about 4% to 5%, versus 1% on placebo¹. Worth a careful note: this is almost certainly not the drug attacking hair follicles directly. Rapid, large weight loss from any cause can trigger telogen effluvium, a temporary shedding phase that typically recovers — the same pattern seen after major weight loss without any drug. We unpack the evidence, the likely mechanism, and when shedding warrants a clinician in does Zepbound cause hair loss.

Gastroesophageal reflux (GERD) — about 4% to 5%, versus 2% on placebo¹. For why slowed gastric emptying drives heartburn and how to ease it, see tirzepatide and acid reflux/heartburn.

Why the dose ladder is the main defense

None of these numbers are static — they track the dose. That is exactly why Zepbound is started at 2.5 mg and raised slowly, in 2.5 mg steps no closer than four weeks apart, up to a maximum of 15 mg¹. The slow climb gives the gut time to adapt and keeps the GI effects in the "mild to moderate" band for most people. Rushing the ladder, or jumping back to a high dose after a gap, is the fastest way to turn manageable nausea into a reason to quit. For when each wave actually peaks and fades, see how long do Zepbound side effects last. The full schedule and practical tolerance tips are in our tirzepatide dosing ladder and side effects guide, and the practical mechanics of giving the shot — sites, rotation, and storage — are in how & where to inject Zepbound.

The serious warnings: rare but real

Common side effects are one thing; the label's warnings are another. These are less frequent but more consequential, and they are the reason Zepbound is prescribed and monitored by a clinician rather than sold over the counter.

Thyroid C-cell tumors (boxed warning). Tirzepatide caused dose-dependent thyroid C-cell tumors in rats; whether it does so in humans is unknown¹. Because of this, Zepbound is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2¹. This is a precaution rooted in animal data, not a confirmed human cancer signal — but it is a hard contraindication for the at-risk groups. We quote the verbatim label text and weigh the rodent-versus-human evidence in the tirzepatide thyroid cancer warning explained.

Acute pancreatitis. Pancreatitis has been reported with GLP-1-based drugs, and the Zepbound label instructs prompt evaluation if it is suspected and discontinuation if confirmed¹. The reassuring context: a tirzepatide-specific safety analysis examining pancreatitis and biliary events did not find that tirzepatide meaningfully raised pancreatitis risk over comparators in the trial data, though the signal is watched closely¹⁰. Severe, persistent abdominal pain — classically radiating to the back — warrants urgent medical attention rather than waiting for the next dose. We unpack the real rate and the red-flag pattern in tirzepatide and pancreatitis.

Gallbladder disease. Acute cholecystitis was reported in 0.7% of Zepbound users versus 0.2% on placebo¹. This fits a broader class pattern: a large meta-analysis of GLP-1 receptor agonist trials found a significantly increased risk of gallbladder and biliary disease, more so at higher doses and longer durations and when used for weight loss⁹. Rapid weight loss itself is an independent gallstone risk factor, so part of this is the weight loss, not only the drug.

Hypoglycemia. On its own in people without diabetes, Zepbound rarely causes low blood sugar. The risk rises sharply when it is combined with insulin or a sulfonylurea — in diabetes trials, hypoglycemia reached about 10% when tirzepatide was paired with a sulfonylurea¹. Anyone on those medicines needs their doses managed by a prescriber.

Reduced oral contraceptive effectiveness, and pregnancy. The label warns that tirzepatide can reduce the absorption of oral birth control pills, and directs patients to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase¹. Zepbound should also not be used in pregnancy. For exactly what to do, see Zepbound, birth control, and pregnancy.

Other labeled precautions. The label also flags acute kidney injury (usually driven by dehydration from severe vomiting or diarrhea), serious hypersensitivity including rare anaphylaxis and angioedema, diabetic retinopathy complications in people with diabetes, acute gallbladder disease, and a risk of pulmonary aspiration under anesthesia because the drug slows gastric emptying — relevant if you have surgery planned¹, which is why it is often paused beforehand; see stopping tirzepatide before surgery and anesthesia. Severe GI reactions occurred in roughly 1.7% to 3.1% of Zepbound users versus about 1% on placebo, and the drug is not recommended in people with severe gastroparesis¹.

How this fits the efficacy tradeoff

Side effects only mean something against the benefit. In SURMOUNT-1, the pivotal obesity trial, mean weight reduction reached roughly 21% at the 15 mg dose over 72 weeks versus about 3% on placebo²; in SURMOUNT-2, adults with both obesity and type 2 diabetes still lost clinically meaningful weight³; and in the SURMOUNT-5 head-to-head, tirzepatide outperformed semaglutide 2.4 mg for weight loss⁵. Zepbound is also FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, on the strength of the SURMOUNT-OSA trial, which showed large reductions in apnea events⁶ — see our full breakdown of Zepbound for sleep apnea. The catch the withdrawal trial made unavoidable: in SURMOUNT-4, people who stopped tirzepatide regained substantial weight while those who continued kept losing⁴. The side effects, in other words, come bundled with a drug that works — and works only while you take it. For the complete picture, see our tirzepatide evidence guide, and for how it stacks up against the other leading option, tirzepatide vs semaglutide.

The honest bottom line

Most Zepbound side effects are gastrointestinal, dose-dependent, and concentrated during dose increases: nausea (about 25-29%), diarrhea (19-23%), constipation (11-17%), and vomiting (8-13%) lead the list, with everything else under roughly 10%¹. For the large majority these are mild to moderate and ease with time and a patient dose ladder⁷. The serious warnings — thyroid C-cell tumors (animal data), pancreatitis, gallbladder disease, and hypoglycemia when combined with other diabetes drugs — are rarer but real, and they are why this is a monitored prescription medicine¹. A newer, still-emerging question is whether GLP-1 drugs raise the risk of NAION, a rare optic-nerve stroke — a signal so far strongest for semaglutide and not on the tirzepatide label; we lay out exactly what the evidence does and doesn't show in tirzepatide and vision loss (NAION). Used the way it is labeled, with a clinician watching the dose, the profile is a manageable tradeoff for substantial, evidence-backed weight loss. One common lifestyle question that touches these warnings — additive nausea, hypoglycemia, and pancreatitis risk — is whether you can drink; see Zepbound and alcohol for the honest answer. For how this side-effect profile matches what users actually report, see Zepbound reviews: what real users (and the trials) report. To weigh your options for getting it, start with our best tirzepatide overview.